Serum concentrations of interleukin 18 and 25-hydroxyvitamin D3 correlate with depression severity in men with psoriasis

PLoS One. 2018 Aug 9;13(8):e0201589. doi: 10.1371/journal.pone.0201589. eCollection 2018.

Abstract

Objective: Psoriasis and depression may have common mechanisms, such as systemic inflammation, dysfunction of the hypothalamic-pituitary-adrenal axis, and vitamin D3 deficiency. Among men with psoriasis, this study examined whether depression severity was associated with serum concentrations of different metabolic and inflammatory markers.

Methods: The study included 85 men with psoriasis (mean age ± standard deviation [SD], 47 ± 14 years) and 65 men without psoriasis (mean age ± SD, 44 ± 13 years). In both groups, we measured the body mass index; blood pressure; and serum concentrations of lipids, uric acid, lipase, interleukins 6 and 18, cortisol, and 25-hydroxyvitamin D3. All participants completed the Beck Depression Inventory. Other variables analyzed included psoriasis duration, the Psoriasis Area Severity Index, and the percentage of body surface area affected by psoriatic lesions.

Results: Compared with controls, patients with psoriasis had significantly greater depression severity, higher body mass indices, and higher serum concentrations of total cholesterol and interleukins 6 and 18; moreover, they had significantly lower serum 25-hydroxyvitamin D3 concentrations. In patients with psoriasis, depression severity correlated positively with psoriasis duration, the Psoriasis Area Severity Index, the percentage of body surface area affected by psoriatic lesions, and interleukin-18 concentration. In patients with psoriasis, depression severity correlated negatively with 25-hydroxyvitamin D3 concentration, but it did not correlate significantly with the serum concentrations of interleukin 6 and cortisol.

Conclusions: High concentrations of interleukin 18 and low concentrations of 25-hydroxyvitamin D3 may be associated with depression severity in men with psoriasis. Thus, further studies should examine whether effective anti-inflammatory treatments or vitamin D3 supplementation can improve depression outcomes in these patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / blood*
  • Calcifediol / blood*
  • Case-Control Studies
  • Depression / blood
  • Depression / diagnosis*
  • Depression / etiology
  • Humans
  • Interleukin-18 / blood*
  • Interleukin-6 / blood*
  • Male
  • Middle Aged
  • Prognosis
  • Psoriasis / complications*
  • Psoriasis / psychology
  • Severity of Illness Index*

Substances

  • Biomarkers
  • IL18 protein, human
  • IL6 protein, human
  • Interleukin-18
  • Interleukin-6
  • Calcifediol

Grants and funding

The study was supported from the Medical University of Lublin funds (grants no. DS 168 and DS 460/2016) (https://www.umlub.pl), and from the Polish National Science Center funds (grant no. UMO-2011/01/N/NZ6/01762) (https://ncn.gov.pl/?language=en). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.